Abstract: Six newly synthesized heterocyclic (2-nitrophenyl)piperazines, with a specific structure of the heteroaryl group, which mimics the catechol moiety of dopamine (benzimidazoles and substituted benzimidazoles), were evaluated for their binding affinity to rat dopamine (DA), serotonin (5-HT) and a 1 receptors. All compounds with a benzimidazole group had a 5-HT 2A /D 2 receptors binding ratio characteristic for atypical neuroleptics (>1, pK i values). Compound 7c, 4-bromo-6-{2-[4-(2-nitrophenyl)piperazin-1-yl]ethyl}-1H-benzimidazole, expressed higher affinities for all receptor classes than clozapine. Also, it exhibited the best characteristic for atypical neuroleptics and presents a compound with the best profile for further in vivo investigations.
INTRODUCTION
One field of intensified research in the area of medicinal chemistry is focused on the design and synthesis of new antipsychotic drugs (APDs) which would express a higher therapeutic efficiency and a wider spectrum of action on schizophrenia symptoms, with minimized extrapyramidal side effects. Conventional APDs, acting by a common mechanism of the blocking of the central dopamine (DA) D 2 receptors, are generally considered to be effective in the treatment of schizophrenics with positive symptoms, 1 while a group of so-called atypical APDs, such as the prototype drug -clozapine, express increased effectiveness in negative affective symptoms, including efficacy in patients resistant to standard therapy. 2 The new genera-tion of therapeutically successful atypical APDs act as both DA and 5-HT system stabilizers. They express partial agoinst activity at the 5-HT 1A receptors and stronger antagonism at the 5-HT 2A than at the D 2 receptors, which is also suggested in literature as a suitable model of interactions for some newly synthesized DA/5-HT ligands which are considered for their atypical neuroleptic potential. [2] [3] [4] Previous studies on benzimidazole type of dopaminergic/serotonergic ligands [5] [6] [7] showed that the affinity and DA/5-HT ratio can be fine tuned by small changes in the structure of the ligand. Following this approach, series of halogenated derivatives of benzimidazoles and benzimidazole-2-thiones, containing (2-nitrophenyl)piperazine moiety, which are expected to have APD-like properties, are presented.
EXPERIMENTAL

General
A Boetius PHMK apparatus (VEB Analytic, Dresden, Germany) was used to determine the melting points (uncorrected). The 1 H-NMR spectra were recorded on a Gemini 2000 spectrometer (Varian, Palo Alto, CA, USA), with CDCl 3 as the solvent unless otherwise stated and are reported in ppm downfield from the internal standard tetramethylsilane. The IR spectra were run on a Perkin Elmer 457 Grating Infrared Spectrophotometer (Perkin Elmer, Beaconsfield, UK). The mass spectra were determined using a Finnigan Mat 8230 mass spectrometer (Finnigan, Bremen, Germany). High-resolution mass spectra were aquired on a Bruker Biflex MALDI TOF (Bruker, Bremen, Germany). For analytical thin-layer chromatography, Merck (Darmstadt, Germany) F-256 plastic-backed thin-layer silica gel plates were used. Chromatographic purifications were performed on Merck-60 silica gel columns, 230-400 mesh ASTM, under medium pressure (MPLC). Solutions were routinely dried over anhydrous Na 2 SO 4 prior to evaporation.
Chemistry
4-(2-Chloroethyl)-2-nitroaniline (1a), 8 2-chloro-4-(2-chloroethyl)-6-nitroaniline (1b) 7 and 2-bromo-4-(2-chloroethyl)-6-nitroaniline (1c) 7 were prepared as previously described.
Stannous chloride (47.5 g, 0.23 mol) was added to a solution of either 4-(2-chloroethyl)-2-nitroaniline (1a) or 2-halo-4-(2-chloroethyl)-6-nitroaniline (1b,c) (40 mmol) in absolute ethanol (85 mL). After 4 h at reflux, the solution was poured onto ice, made alkaline with 5 M NaOH and extracted with EtOAc. The extracts were dried and the solvent was removed in vacuo. The resulting diamine (2a, 2b or 2c) was immediately used without further purification. The obtained diamine (2a, 2b or 2c) (21 mmol) was dissolved at 0°C in a mixture of dioxane (65 mL) and 1M NaOH (65 mL). To this solution, di-tert-butyl dicarbonate (6.9 g, 31.5 mmol) was added at 0°C and after 2 h at this temperature, the reaction mixture was stirred overnight at room temperature. 3 .65 (t, 2H, J = 7.6 Hz), 6.27 (s, 2H, NH), 7.14 (d, 1H, J = 2 Hz, ArH), 7.21 (s, 1H, ArH). 
General procedure for the synthesis of tert-butyl 2-[(tert-butoxycarbonyl)amino]-4-{2-[4-(2-nitrophenyl)piperazin-1-yl]ethyl}phenylcarbamate (4a) and tert-butyl 2-[(tert-butoxycarbonyl)ami -no]-3-halo-5-{2-[4-(2-nitrophenyl)piperazin-1-yl]ethyl}phenylcarbamates
tert-butyl 2-[(tert-bu- toxycarbonyl)amino]-4-(2-chloroethyl)phenylcarbamate (3a) or tert-butyl 2-[(tert-butoxycarbo- nyl)amino]-3-halo-5-(2-chloroethyl)phenylcarbamate (3b,c
General procedure for the synthesis of 2-amino-4-{2-[4-(2-nitrophenyl)piperazin-1-yl]ethyl}phe-nylamine (5a) and 2-amino-3-halo-5-{2-[4-(2-nitrophenyl)piperazin-1-yl]ethyl}phenylamines (5b and 5c).
Hydrochloric acid (37%, 10 mL) was added under stirring to a solution of either tert-butyl
0 mmol) in 20 ml EtOH at RT. After 60 min, the solvent was evaporated in vacuo. The residue was extracted with a mixture of 20 ml 10 % NaHCO 3 and 20 mL chloroform, the organic phase was separated, dried over Na 2 SO 4 , and evaporated in vacuo. The obtained products were used without further purification for the synthesis of compounds 6a-c and 7a-c.
Synthesis of 5-{2-[4-(2-nitrophenyl)piperazin-1-yl]ethyl}-1,3-dihydro-2H-benzimidazole-2-thione (6a) and 4-halo-6-{2-[4-(2-nitrophenyl)piperazin-1-yl]ethyl}-1,3-dihydro-2H-benzimidazole-2-thi ones (6b,c).
Carbon disulfide (0.24 mL, 4 mmol) and KOH (0.25 g in 0.6 mL water) were added to 2 mmol of diamine (5a,b or c) in 10 mL EtOH. After refluxing for 3 h, 0.3 mL of acetic acid in 3.3 mL water were added. The solvent was removed in vacuo and the residue purified by silica gel column chromatography using a 0-5% MeOH gradient in CH 2 
Synthesis of 5-{2-[4-(2-nitrophenyl)piperazin-1-yl]ethyl}-1H-benzimidazole (7a) and 4-halo-6-{2-[4-(2-nitrophenyl)piperazin-1-yl]ethyl}-1H-benzimidazoles (7b,c).
2 mmol of diamine (5a,b or c) and 0.44 mL (7.3 mmol) of 98% formic acid were heated in an oil bath at 100°C for 2 h. After cooling to ambient temperature, 15 mL of 10% NaHCO 3 were added and the product extracted with CH 2 Cl 2 . The solvent was removed in vacuo and the residue purified by silica gel column chromatography using a 0-3% MeOH gradient in CH 2 (10 -5 -10 -9 M) of the selected compound. Non-specific binding was measured in the presence of (+)-butaclamol (D 2 ), serotonine (5HT 1A ), ketanserin (5HT 2A ) and prazosine (a 1 ). The retained radioactivity was measured by introducing dry filters and 5 mL toluene-based scintillation liquid and counted in a 1219 Rackbeta Wallac scintillation counter.
Competition binding curves were constructed and analyzed by "GraphPad Prysm" (v. 4.0.). Values are the means of 3-4 independent experiments done in duplicate performed at five competing ligand concentrations (10 -5 -10 -9 M) with
RESULTS AND DISCUSSION
Several new 5-{2-[4-(2-nitrophenyl)piperazin-1-yl]ethyl}-1,3-dihydro-2H-benzimidazole-2-thiones and 5-{2-[4-(2-nitrophenyl)piperazin-1-yl]ethyl}-1H-benzimidazoles (compounds 6a-c and 7a-c, respectively) were synthesized as shown in Scheme 1. In short, 4-(2-chloroethyl)-2-nitroaniline (1a) or 4-(2-chloroethyl)-2-halo-6-nitroaniline (1b,c) were reduced with stannous chloride in absolute ethanol, and the resulting diamines 2a-c were converted into di-tBOC derivatives 3a-c, using di-tert-butyl dicarbonate. The compounds readily alkylated 1-(2-nitrophenyl)piperazine in the presence of potassium carbonate and potassium iodide in DMF. Diamines 5a-c were obtained by hydrolyzing the di-tBOC derivatives with 4M HCl in ethanol. Benzimidazole-2-thiones 6a-c and benzimidazoles 7a-c were synthesized from the corresponding diamines with CS 2 /KOH in EtOH and formic acid, respectively. The binding affinities were evaluated by specific in vitro assays for the DA (D 2 ), 5-HT (5-HT 1A and 5-HT 2A ) and a 1 -adrenergic receptors. These receptors were chosen in accordance to the serotonin-dopamine hypothesis of schizophrenia and with regards to their anticipated roles in the action of atypical APDs. 3, 4 The significance of ligand interaction with adrenergic receptors was also suggested, as their blockage may stabilize dysregulated central dopaminergic systems in schizophrenia. 10 Specific binding affinities (pK i values, Table I ) of the newly synthesized compounds and clozapine, the prototype of atypical APD, were determined by measuring the extent of displacement of 3 H-labelled specific ligands from rat striatal or cortical synaptosomes with a range of concentrations of the compounds. 9, 11 In previous studies on ligand-D 2 dopamine receptor interactions, it was noticed that the binding affinity depends substantially on the structure of the arylpiperazine part of molecule. 6 In addition to general structural requirements, it was clearly shown that substituents able to participate in hydrogen bond formation (nitro or methoxy) in position 2 of the phenyl ring in the piperazine part of a ligand forming one more hydrogen bond, with Trp 182 (VI.48) (an amino acid highly conserved through the A class of the G protein-coupled receptor family), increase the binding affinities. 5 Additionally, a study of the effects of halogens on the electron density of the benzimidazole benzene ring raised the hypothesis that electron-withdrawing substituents have a strong influence on the electrostatic surface potential of a ligand, which is an important factor in the interaction with the receptors binding pocket. 7 Our leading idea was to combine those two effects by the synthesis of halogenated (2-nitrophenyl)piperazines and to compare their binding affinities with the parent, non-substituted (2-nitrophenyl)piperazines.
N-(-2-NITROPHENYL)PIPERAZINE
All compounds (parent, benzimidazole-2-thione and benzimidazole, and halogen substituted ligands) expressed a higher affinity for the D 2 and 5HT 1A receptors comparing to clozapine, while only benzimidazole series of the compounds showed increased affinity for the a 1 -adrenergic receptor. Binding potency towards 5HT 2A receptors, similar to clozapine, were expressed only by (2-nitrophenyl)piperazines with the benzimidazole moiety, where compound 7c showed a somewhat higher affinity for the 5HT 2A receptors than clozapine [pK i (K i ) values of 8 (10 nM) and 7.88 (13.2 nM), respectively].
The results of the investigations justify our hypothesis that the introduction of a halogen atom in the heterocyclic, benzimidazole-like, part of the (2-nitrophenyl)piperazine molecule would result in a higher affinity for D 2 DAR. On the other hand, the benzimidazole series of the ligands showed a binding potency towards 5HT 2A receptors similar to that of clozapine and all of them showed a 5HT 2A /D 2 binding ratio characteristic for atypical APDs (>1, pK i values). Only in the case of compound 7c the introduction of the halogen atom result in an increase of the selectivity towards 5HT 2A receptors.
Taking all this into account, 4-bromo-6-{2-[4-(2-nitrophenyl)piperazin-1-yl]ethyl}-1H-benzimidazole (7c) exhibited the most suitable 5HT 2A /D 2 binding ratio (1.14, pK i value) and showed all prerogatives characteristic for atypical neuroleptics and suggests this compound to be a good pretender for further in vivo testing.
Sintetisano je {est heterocikli~nih (2-nitrofenil)piperazina sa specifinom heteroaril grupom, koja podra`ava kateholsku grupu dopamina (benzimidazoli i supstituisani benzimidazoli), i ispitan je wihov afinitet ka dopaminskim, serotoninskim i a 1 receptorima. Sva jediwewa sa benzimidazolskim grupama su pokazala 5-HT 1A /D 2 odnos vezivawa karakteristi~an za atipi~ne neuroleptike (>1, pK i vrednosti). Jediwewe 7c, 4-bromo-6-{2-[4-(2-nitrofenil)piperazin-1-il]etil}-1H-benzimidazol, pokazalo je izra`eniji afinitet ka svim klasama receptora u pore|ewu sa klozapinom i tako|e predstavqa jediwewe sa najboqim karakteristikama za daqa in vivo istra`ivawa.
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